Clinical Trials Logo

Clinical Trial Summary

Multicentre randomised (1:1) trial assessing the efficacy of whole brain radiotherapy in addition to Gefitinib for the management of brain metastasis in lung cancer patients with a mutated EGFR.


Clinical Trial Description

Lung cancer patients with newly diagnosed CNS metastasis with- at least one brain lesion measuring > 1 cm in longest dimension - not eligible for surgery or stereotactic radio-surgeryOpen-label, multicentre, national, randomised (1:1) phase II trialArm A: WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance Arm B: Gefitinib ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01363557
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Terminated
Phase N/A
Start date March 2012
Completion date May 2013

See also
  Status Clinical Trial Phase
Withdrawn NCT01913067 - Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC Phase 2
Completed NCT02662725 - Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases Phase 2
Completed NCT00406835 - Prospective Randomized Trial Between WBRT Plus SRS Versus SRS Alone for 1-4 Brain Metastases Phase 3
Completed NCT01724801 - Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer Phase 3
Completed NCT00219297 - Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02328300 - FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions
Terminated NCT01324635 - Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors Phase 1
Terminated NCT01894633 - Study of Whole-brain Irradiation With Chloroquine for Brain Metastases Phase 2
Recruiting NCT02681549 - Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Phase 2
Terminated NCT02279992 - Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases Early Phase 1
Completed NCT02913534 - Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy N/A
Completed NCT01942980 - Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer Phase 3
Active, not recruiting NCT05102747 - Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation. N/A
Recruiting NCT01891708 - VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer N/A
Completed NCT01508221 - Evaluation of the Use of Trental and Vitamin E For Prophylaxis of Radiation Necrosis Phase 2
Completed NCT00587964 - Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases Phase 2
Not yet recruiting NCT02832635 - A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases Phase 2
Completed NCT01395407 - Phase I Trial of Stereotactic Radiosurgery Following Surgical Resection of Brain Metastases Phase 1
Terminated NCT02433171 - Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery
Recruiting NCT02504788 - A Prospective Study of the Impact of Hippocampal Avoidance During Whole Brain Radiotherapy on Neurocognitive Function Decline N/A